Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling an openness to new approaches that haven’t been validated and the National ...

The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug developmen ...

Non-animal testing methods could save drugmakers time and money, officials say ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...

The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in ...

The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for certain drug products, starting with monoclonal antibodies. This shift ...

(Reuters) -Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near ...

Animal testing in Connecticut rakes in millions in federal dollars each year at colleges and universities but, the National Institutes of Health recently announced it is pivoting from using just ...

Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing, according to the non-profit animal rights organization People ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs and biological products “with ...

Today’s animal testing differs from how it was back in the day. It’s typically done on a specific ingredient rather than a finished product, and there are often regulatory requirements based on ...